In 50 patients with end-stage renal disease on maintenance hemodialysis, 2-D echocardiography revealed diastolic dysfunction in 52% and left ventricular hypertrophy in 48% of patients.
Cross-Sectional (n=50)
No
What is the prevalence of 2-D echocardiographic abnormalities in asymptomatic ESRD patients on maintenance hemodialysis?
Echocardiographic screening in ESRD patients frequently reveals structural and functional abnormalities like left ventricular hypertrophy and diastolic dysfunction, which are particularly prevalent in those with concurrent anemia and hypertension.
Chronic kidney disease (CKD) is a major public health problem worldwide with increase in incidence and prevalence. Diabetes and hypertension are the leading cause of CKD worldwide, whereas hypertension is a cause as well as effect of CKD. CKD is a risk factor for cardiovascular events and complications which increase as CKD progress to ESRD 3. Cardiovascular mortality is 10-20 times more common in ESRD patients on renal replacement therapy as compared to general population. One of the major structural cardiac abnormalities in CKD patients is left ventricular hypertrophy (LVH) and is associated with increased risk for cardiac ischemia, congestive heart failure, as well as a very strong independent predictor for cardiovascular mortality 4. Majority patients with CKD die due to cardiovascular events before reaching ESRD due to risk factors 5. Anemia and hypertension are most consistent with heart failure that causes 2/3rd death of all dialysis patients. ESRD patients do have myriads of structural and functional cardiac abnormalities which include LVH, depressed LV function, regional wall motion abnormality, pericardial effusion and valvular calcification.
Patel et al. (Tue,) conducted a cross-sectional in End Stage Renal Disease (ESRD) (n=50). 2-D Echocardiography was evaluated on Prevalence of diastolic dysfunction. In 50 patients with end-stage renal disease on maintenance hemodialysis, 2-D echocardiography revealed diastolic dysfunction in 52% and left ventricular hypertrophy in 48% of patients.